Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -15.40 -1.02% 1,499.40 1,502.60 1,503.40 1,534.20 1,490.40 1,524.20 7,628,120 16:35:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 16.0 75,226

Glaxosmithkline Share Discussion Threads

Showing 19176 to 19199 of 21125 messages
Chat Pages: Latest  773  772  771  770  769  768  767  766  765  764  763  762  Older
DateSubjectAuthorDiscuss
08/2/2019
11:31
DrB - the two deals I mention have yet to hit published numbers as post 31.12.2018.
alphorn
08/2/2019
11:21
Most of the debt increase is for the buyout of the JV from Novartis. I guess this is offset by the increased earnings from owning the remainder. Presumably a lot of this debt will be attached to the consumer healthcare division if/once it is spun off.
dr biotech
08/2/2019
10:38
I am surprised that no one has commented on #154. The Q1/2 impact of the recent deals (post 2018 balance sheet) will be huge on GSK's gearing. Perhaps once the next numbers come out the analysts will wake up.
alphorn
08/2/2019
10:33
I see 1475p, when they go ex div.
montyhedge
08/2/2019
09:00
You guys shorting now at 1560?
zicopele
07/2/2019
19:50
Yes short at 1550p seems to work.
montyhedge
07/2/2019
18:18
I've been able to grab a bit of extra pocket money by putting a small short on GSK every time it goes up a decent amount during the day because it literally always goes down by end of day every single time without fail. People talking about debt being a concern simply don't understand what is going to happen re: the consumer unit. It's an excellent strategy.
romeike
07/2/2019
18:15
Tesaro deal plus Merck for Q1 2019 don't forget which will hit cash/debt. I am out for now - all this new stuff is jam tomorrow.
alphorn
07/2/2019
16:43
This may sound stupid, but I remember when Fred Goodwin RBS doing massive deals with debt, you can expand to quickly it all went pear shaped, I hope GSK CEO who is good,sees our these mergers and acquisitions pan out, before anymore.
montyhedge
07/2/2019
15:54
The increased debt is a concern. GSK is no bond. risk of dividend cut given the very significant increase in debt. Basically the dividend for the last two years funded by debt increase. This is unsustainable.
zicopele
07/2/2019
15:15
Monty - "watch the last hour of trade before close, thats when the funds come in." I'm just a simple PI but I have wondered about last hour trades. Can you expand please ? What is the rational behind the 'funds' pilling in during last hour trading. Just interested, thanks :-)
losos
07/2/2019
13:54
80p for years in future, GSK its shares is just like the GSK corporate bond, except shares of course more risk.Treat ord as a bond, I suppose with no dividend growth.
montyhedge
07/2/2019
09:32
Earnings call transcript in case anyone interested. GlaxoSmithKline (GSK) CEO Emma Walmsley on Q4 2018 Results - Earnings Call Transcript hTTps://seekingalpha.com/article/4238727-glaxosmithkline-gsk-ceo-emma-walmsley-q4-2018-results-earnings-call-transcript
wbecki
07/2/2019
08:51
Thanks for the reply h-e. You've confirmed what was implied in my question, which is that current FCF cover is not much use as an indicator of future dividends because of the volatility arising from the one-offs that you list. With 2019 profits expected to be lower too, and the Consumer Healthcare side of the company being hived off, FCF cover in the near future is not exactly transparent anyway. I'm just happy that the 80p divi is maintained for now, and wasn't expecting any increase this year or next. Just wonder why the final results mention the metric of 1.25x to 1.5x cover at all.
broadgreen
07/2/2019
08:48
Surely not many selling 23p quarterly div ex in a couple of weeks. I would have thought get that then sell.
montyhedge
07/2/2019
07:09
Don't know this posted twice, repetition deleted
hydrogen economy
07/2/2019
07:09
Broadgreen As you say Div was very well covered by FCF in 2018 (indeed Q418 FCF at 3.3b almost covered the FY divis),but it was distorted by one offs :- -Reduction of inventory balances -favourable timing of payments for returns and rebates -reduced legal settlement costs and restructuring payments, -lower capital expenditure -increased disposals of intangible assets of £256 million But Profits expected to drop again next year and one-offs could well go the other way. The number of deals being done means lots of one-off costs so I think no certainty of a rise in 2020, we can only watch and hope.
hydrogen economy
07/2/2019
03:39
Glaxo hunts more deals to stay competitive, Walmsley says hTtps://www.telegraph.co.uk/business/2019/02/06/glaxo-hunts-deals-stay-competitive-walmsley-says/ GlaxoSmithKline strategy revamp and shingles drug help boost earnings htTps://www.ft.com/content/5eabccc2-2a01-11e9-a5ab-ff8ef2b976c7
xxxxxy
06/2/2019
17:31
Net debt has increased from 13bn to 21bn. We better start generating bigger profits.
zicopele
06/2/2019
16:55
Can’t see why any of us is not delighted at the share price movement over the last two days, except anhar, of course, to whom it does not matter!
jadeticl3
06/2/2019
16:40
You must have said the same thing now over ten times in January..why?
badtime
06/2/2019
16:10
Emma Walmsley, CEO, GSK, summarises our performance in 2018 hTTps://www.youtube.com/watch?time_continue=348&v=CLBhM5O6c0Y
wbecki
06/2/2019
16:08
Looks like another test of 1600 on the cards.
tim 3
06/2/2019
15:43
Don't worry about it,such concerns are discounted in the current rating.
steeplejack
Chat Pages: Latest  773  772  771  770  769  768  767  766  765  764  763  762  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200408 15:51:12